胃癌手术后替吉奥单药口服化疗的临床疗效

Clinical research of gastric cancer patients treated with single S-1 after operation

目的:观察可手术的胃癌患者术后替吉奥单药的临床应用及其效果。方法:以临床分期Ⅱ期及Ⅲ期胃癌患者,并经手术治疗后获得痊愈者为入选对象,术后1个月试验组给予替吉奥胶囊口服,用量为80mg/(m2·d),早晚分次口服,d1-14。对照组给于FOLFOX4标准方案,每2周作为一个周期,3周期后评价疗效。结果:试验组与对照组比较:在不良反应发生率、KPS评分级别、临床获益率、有效率、患者手术后2年生存率均无明显统计学差异。结论:胃癌手术后应用替吉奥单药控制,不良反应轻微,术后2年生存率与对照组相比无统计学差异,治疗依从性较好,值得推广应用。

Objective：To observe clinical application and results of patients with operable gastric cancer treated with S-1 monotherapy. Methods：Clinical stage Ⅱ and Ⅲ patients with gastric cancer,and after surgery to get healed were selected as objects,the test group was given S-1 after one month,with dosage of 80mg/（m2·d）,divid-ed doses in morning and night,day 1-14 medication;Control group was given standard regimen：FOLFOX4,every two weeks as a period. Finally,two groups were evaluated after 3 cycles. Results：In two groups,incidence of adverse reac-tions,KPS score level,clinical benefit rate,efficient rate,2-year survival rate of patients after surgery,were no signif-icant statistical difference. Conclusion：For gastric cancer patients after surgery with S-1 single drug treatment,ad-verse reactions are mild,and there were no significant difference between the test group and the control group on 2-year survival rate,and treatment compliance.